Do analysts rate AQB or JSPR?

Jasper Therapeutics has a consensus price target of $8.17, indicating a potential upside of 1,221.89%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is AQB or JSPR more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% Jasper Therapeutics N/A -884.17% -143.83%

Does the media prefer AQB or JSPR?

In the previous week, Jasper Therapeutics had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.59 beat Jasper Therapeutics' score of -0.21 indicating that AquaBounty Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AquaBounty Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GNTA or AQB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, GNTA or AQB?

Genenta Science has higher earnings, but lower revenue than AquaBounty Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A AquaBounty Technologies $2.47M 2.38 -$18.49M -$0.82 N/A

Is GNTA or AQB more profitable?

Genenta Science's return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A AquaBounty Technologies N/A -147.07% -28.73%

Does the media favor GNTA or AQB?

In the previous week, Genenta Science and Genenta Science both had 2 articles in the media. AquaBounty Technologies' average media sentiment score of 0.59 beat Genenta Science's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AquaBounty Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AKTX or AQB?

Akari Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 252.98%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Akari Therapeutics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, AKTX or AQB?

Akari Therapeutics has higher earnings, but lower revenue than AquaBounty Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A AquaBounty Technologies $2.47M 2.38 -$18.49M -$0.82 N/A

Is AKTX or AQB more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -147.45% -74.70% AquaBounty Technologies N/A -147.07% -28.73%

Does the media refer more to AKTX or AQB?

In the previous week, AquaBounty Technologies had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Akari Therapeutics. AquaBounty Technologies' average media sentiment score of 0.59 beat Akari Therapeutics' score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AquaBounty Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AQB or LGVN?

Longeveron has a consensus target price of $80.00, suggesting a potential upside of 3,112.85%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor AQB or LGVN?

In the previous week, Longeveron had 8 more articles in the media than AquaBounty Technologies. MarketBeat recorded 10 mentions for Longeveron and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.59 beat Longeveron's score of -0.09 indicating that AquaBounty Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AquaBounty Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer QNTM or AQB?

Quantum Biopharma currently has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Quantum Biopharma is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QNTM or AQB more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% AquaBounty Technologies N/A -147.07% -28.73%

Does the media favor QNTM or AQB?

In the previous week, Quantum Biopharma had 4 more articles in the media than AquaBounty Technologies. MarketBeat recorded 6 mentions for Quantum Biopharma and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.59 beat Quantum Biopharma's score of 0.30 indicating that AquaBounty Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AquaBounty Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AquaBounty Technologies (AQB) Competitors

$1.14 +0.01 (+0.88%)

As of 09/18/2026 04:00 PM Eastern

Compare

AQB vs. JSPR, GNTA, AKTX, LGVN, and QNTM

Should you buy AquaBounty Technologies stock or one of its competitors? AquaBounty Technologies's main competitors and comparable companies include Jasper Therapeutics (JSPR), Genenta Science (GNTA), Akari Therapeutics (AKTX), Longeveron (LGVN), and Quantum Biopharma (QNTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AquaBounty Technologies compare to Jasper Therapeutics?

AquaBounty Technologies (NASDAQ:AQB) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market.

AquaBounty Technologies has higher revenue and earnings than Jasper Therapeutics. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.38	-$18.49M	-$0.82	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

In the previous week, Jasper Therapeutics had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.59 beat Jasper Therapeutics' score of -0.21 indicating that AquaBounty Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AquaBounty Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jasper Therapeutics has a consensus price target of $8.17, indicating a potential upside of 1,221.89%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AquaBounty Technologies' return on equity of -147.07% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Summary

Jasper Therapeutics beats AquaBounty Technologies on 8 of the 14 factors compared between the two stocks.

How does AquaBounty Technologies compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Genenta Science has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Genenta Science has higher earnings, but lower revenue than AquaBounty Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
AquaBounty Technologies	$2.47M	2.38	-$18.49M	-$0.82	N/A

In the previous week, Genenta Science and Genenta Science both had 2 articles in the media. AquaBounty Technologies' average media sentiment score of 0.59 beat Genenta Science's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AquaBounty Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genenta Science's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
AquaBounty Technologies	N/A	-147.07%	-28.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Genenta Science beats AquaBounty Technologies on 5 of the 8 factors compared between the two stocks.

How does AquaBounty Technologies compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, AquaBounty Technologies had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Akari Therapeutics. AquaBounty Technologies' average media sentiment score of 0.59 beat Akari Therapeutics' score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AquaBounty Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Akari Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 252.98%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Akari Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AquaBounty Technologies' return on equity of -147.07% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Akari Therapeutics has higher earnings, but lower revenue than AquaBounty Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
AquaBounty Technologies	$2.47M	2.38	-$18.49M	-$0.82	N/A

Akari Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Summary

AquaBounty Technologies beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks.

How does AquaBounty Technologies compare to Longeveron?

AquaBounty Technologies (NASDAQ:AQB) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

AquaBounty Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Longeveron has a consensus target price of $80.00, suggesting a potential upside of 3,112.85%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Longeveron had 8 more articles in the media than AquaBounty Technologies. MarketBeat recorded 10 mentions for Longeveron and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.59 beat Longeveron's score of -0.09 indicating that AquaBounty Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AquaBounty Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

AquaBounty Technologies has higher revenue and earnings than Longeveron. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.38	-$18.49M	-$0.82	N/A
Longeveron	$1.19M	6.69	-$22.70M	-$9.90	N/A

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AquaBounty Technologies has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. AquaBounty Technologies' return on equity of -147.07% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Longeveron	-1,977.59%	-223.19%	-150.20%

Summary

AquaBounty Technologies and Longeveron tied by winning 8 of the 16 factors compared between the two stocks.

How does AquaBounty Technologies compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Quantum Biopharma currently has a consensus price target of $8.00, suggesting a potential upside of 118.58%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Quantum Biopharma is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AquaBounty Technologies' return on equity of -147.07% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
AquaBounty Technologies	N/A	-147.07%	-28.73%

AquaBounty Technologies has higher revenue and earnings than Quantum Biopharma. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
AquaBounty Technologies	$2.47M	2.38	-$18.49M	-$0.82	N/A

Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

In the previous week, Quantum Biopharma had 4 more articles in the media than AquaBounty Technologies. MarketBeat recorded 6 mentions for Quantum Biopharma and 2 mentions for AquaBounty Technologies. AquaBounty Technologies' average media sentiment score of 0.59 beat Quantum Biopharma's score of 0.30 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AquaBounty Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

AquaBounty Technologies beats Quantum Biopharma on 8 of the 14 factors compared between the two stocks.

Get AquaBounty Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQB vs. The Competition

Export

Metric	AquaBounty Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.87M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-1.39	14.23	275.49	25.40
Price / Sales	2.38	1,440.84	644.44	86.30
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	-2.33	15.45	10.46	6.33
Net Income	-$18.49M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-6.56%	-1.21%	0.59%	1.12%
1 Month Performance	-12.98%	-3.29%	-1.74%	-2.39%
1 Year Performance	-25.97%	37.74%	18.13%	5.35%

AquaBounty Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQB AquaBounty Technologies	0.7042 of 5 stars	$1.14 +0.9%	N/A	-26.0%	$5.87M	$2.47M	N/A	100	News Coverage
JSPR Jasper Therapeutics	1.955 of 5 stars	$0.71 +0.1%	$8.17 +1,051.2%	-75.3%	$23.61M	N/A	N/A	20	News Coverage Analyst Downgrade
GNTA Genenta Science	0.6551 of 5 stars	$0.99 +3.2%	N/A	-76.0%	$22.65M	N/A	N/A	7	News Coverage Gap Down
AKTX Akari Therapeutics	2.5733 of 5 stars	$10.96 -4.4%	$32.33 +195.0%	-71.8%	$22.33M	N/A	N/A	9	News Coverage Gap Down
LGVN Longeveron	2.3122 of 5 stars	$6.65 -2.3%	$80.00 +1,103.0%	-68.3%	$21.71M	$1.20M	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQB) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AquaBounty Technologies (AQB) Competitors

AQB vs. JSPR, GNTA, AKTX, LGVN, and QNTM

How does AquaBounty Technologies compare to Jasper Therapeutics?

Summary

How does AquaBounty Technologies compare to Genenta Science?

Summary

How does AquaBounty Technologies compare to Akari Therapeutics?

Summary

How does AquaBounty Technologies compare to Longeveron?

Summary

How does AquaBounty Technologies compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB vs. The Competition

AquaBounty Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AquaBounty Technologies (AQB) Competitors

AQB vs. JSPR, GNTA, AKTX, LGVN, and QNTM

How does AquaBounty Technologies compare to Jasper Therapeutics?

Which has more risk & volatility, AQB or JSPR?

Which has higher earnings and valuation, AQB or JSPR?

Does the media prefer AQB or JSPR?

Do analysts rate AQB or JSPR?

Do insiders & institutionals have more ownership in AQB or JSPR?

Is AQB or JSPR more profitable?

Summary

How does AquaBounty Technologies compare to Genenta Science?

Which has more risk & volatility, GNTA or AQB?

Which has better valuation & earnings, GNTA or AQB?

Does the media favor GNTA or AQB?

Do insiders and institutionals believe in GNTA or AQB?

Is GNTA or AQB more profitable?

Do analysts recommend GNTA or AQB?

Summary

How does AquaBounty Technologies compare to Akari Therapeutics?

Does the media refer more to AKTX or AQB?

Do institutionals and insiders believe in AKTX or AQB?

Do analysts prefer AKTX or AQB?

Is AKTX or AQB more profitable?

Which has preferable valuation and earnings, AKTX or AQB?

Which has more volatility and risk, AKTX or AQB?

Summary

How does AquaBounty Technologies compare to Longeveron?

Which has more volatility & risk, AQB or LGVN?

Do analysts prefer AQB or LGVN?

Does the media favor AQB or LGVN?

Which has preferable valuation and earnings, AQB or LGVN?

Do institutionals & insiders hold more shares of AQB or LGVN?

Is AQB or LGVN more profitable?

Summary

How does AquaBounty Technologies compare to Quantum Biopharma?

Do analysts prefer QNTM or AQB?

Is QNTM or AQB more profitable?

Which has stronger earnings & valuation, QNTM or AQB?

Which has more risk and volatility, QNTM or AQB?

Does the media favor QNTM or AQB?

Do insiders & institutionals hold more shares of QNTM or AQB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB vs. The Competition

AquaBounty Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools